In both anti-CTLA-4-treated and anti-PD-1-treated patients with melanoma, increases in intratumoral T cells while on treatment were associated with clinical activity, while a higher proximity of CD68+ myeloid cells to CD8+ T cells was documented in non-responders to anti-PD-1. The gene discussed is CTLA4; the disease is melanoma.